Unlocking the potential of allogeneic Vδ2 T cells for ovarian cancer therapy through CD16 biomarker selection and CAR/IL-15 engineering
Abstract Allogeneic Vγ9Vδ2 (Vδ2) T cells have emerged as attractive candidates for developing cancer therapy due to their established safety in allogeneic contexts and inherent tumor-fighting capabilities. Nonetheless, the limited clinical success of Vδ2 T cell-based treatments may be attributed to...
Main Authors: | Derek Lee, Zachary Spencer Dunn, Wenbin Guo, Carl J. Rosenthal, Natalie E. Penn, Yanqi Yu, Kuangyi Zhou, Zhe Li, Feiyang Ma, Miao Li, Tsun-Ching Song, Xinjian Cen, Yan-Ruide Li, Jin J. Zhou, Matteo Pellegrini, Pin Wang, Lili Yang |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Portfolio
2023-11-01
|
Series: | Nature Communications |
Online Access: | https://doi.org/10.1038/s41467-023-42619-2 |
Similar Items
-
Minimally Invasive Preclinical Monitoring of the Peritoneal Cavity Tumor Microenvironment
by: Zachary Spencer Dunn, et al.
Published: (2022-03-01) -
Targeting Immunosuppressive Tumor-Associated Macrophages Using Innate T Cells for Enhanced Antitumor Reactivity
by: Yan-Ruide Li, et al.
Published: (2022-06-01) -
Human γδ T Cell Subsets and Their Clinical Applications for Cancer Immunotherapy
by: Derek Lee, et al.
Published: (2022-06-01) -
Development of Stem Cell-Derived Immune Cells for Off-the-Shelf Cancer Immunotherapies
by: Yan-Ruide Li, et al.
Published: (2021-12-01) -
Engineering Induced Pluripotent Stem Cells for Cancer Immunotherapy
by: Yang Zhou, et al.
Published: (2022-05-01)